Related Experiment Video
Updated: Jul 11, 2025
Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Liposomal nanocarriers containing siRNA as small molecule-based drugs to overcome cancer drug resistance
Mohsen Safaei1, Fatemeh Khalighi2, Fatemeh Akhavan Behabadi2
1Department of Tissue Engineering, School of Advanced Technologies in Medicine, Fasa University of Medical Sciences, Fasa, 7461686688, Iran.
Abstract:
This review discusses the application of nanoliposomes containing siRNA/drug to overcome multidrug resistance for all types of cancer treatments. As drug resistance-associated factors are overexpressed in many cancer cell types, pumping chemotherapy drugs out of the cytoplasm leads to an inadequate therapeutic response. The siRNA/drug-loaded nanoliposomes are a promising approach to treating multidrug-resistant cancer, as they can effectively transmit a small-molecule drug into the target cytoplasm, ensuring that the drug binds efficiently. Moreover, nanoliposome-based therapeutics with advances in nanotechnology can effectively deliver siRNA to cancer cells. Overall, nanoliposomes have the potential to effectively deliver siRNA and small-molecule drugs in a targeted manner and are thus a promising tool for the treatment of cancer and other diseases.
Insights
Nanoliposomes carrying small interfering RNA (siRNA) and drugs offer a novel strategy to combat multidrug resistance in cancer. These nanocarriers enhance drug delivery to cancer cells, improving therapeutic outcomes.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- Multidrug resistance (MDR) in cancer is a significant challenge, often caused by overexpressed drug efflux pumps.
- This leads to inadequate chemotherapy drug concentrations within cancer cells, resulting in poor therapeutic responses.
- Targeted delivery systems are needed to overcome these resistance mechanisms.
Purpose of the Study:
- To review the application of nanoliposomes for co-delivery of siRNA and drugs in treating multidrug-resistant cancers.
- To highlight the potential of nanoliposome-based therapeutics in enhancing chemotherapy efficacy.
- To discuss advancements in nanotechnology for targeted cancer treatment.
Main Methods:
- Nanoliposomes encapsulating siRNA and small-molecule drugs.
- Targeted delivery of therapeutic payloads into cancer cell cytoplasm.
- Utilizing nanotechnology for enhanced siRNA and drug transport.
Main Results:
- Nanoliposomes effectively deliver both siRNA and small-molecule drugs to target cancer cells.
- Co-delivery enhances drug binding efficiency within the cytoplasm.
- Overcomes MDR by bypassing efflux pump mechanisms.
Conclusions:
- Nanoliposomes represent a promising platform for overcoming multidrug resistance in cancer therapy.
- Targeted delivery of siRNA and drugs via nanoliposomes improves treatment efficacy.
- This approach holds potential for treating various cancers and other diseases.
More Related Videos
15:55Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
Published on: June 21, 2013
08:31Porous Silicon Microparticles for Delivery of siRNA Therapeutics
Published on: January 15, 2015
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:15Experimental RNAi
02:56Treatment Resistant Cancers
02:30Small interfering RNAs (siRNA)
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...